Stockscreener 앱 받기
43.58
0.57%
-0.25
시간 외 거래:
43.60
0.02
+0.05%
전일 마감가:
$43.83
열려 있는:
$43.52
하루 거래량:
2.49M
Relative Volume:
0.92
시가총액:
$11.68B
수익:
$2.17B
순이익/손실:
$521.27M
주가수익비율:
24.62
EPS:
1.77
순현금흐름:
$633.79M
1주 성능:
-5.75%
1개월 성능:
+0.32%
6개월 성능:
-1.63%
1년 성능:
+28.40%
1일 변동 폭
$43.00
$43.73
1주일 범위
$43.00
$46.29
52주 변동 폭
$31.90
$49.62
Exelixis Inc Stock (EXEL) Company Profile
명칭
Exelixis Inc
전화
(650) 837-7000
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
EXEL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
43.58 | 11.75B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-11-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | 재개 | Barclays | Equal Weight |
| 2025-09-17 | 재개 | Barclays | Equal Weight |
| 2025-09-17 | 개시 | Goldman | Buy |
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2024-09-19 | 개시 | UBS | Neutral |
| 2024-04-11 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 개시 | BTIG Research | Buy |
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-09-26 | 개시 | H.C. Wainwright | Buy |
| 2023-08-22 | 재확인 | Oppenheimer | Outperform |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 재개 | Piper Sandler | Overweight |
| 2023-03-09 | 개시 | Wells Fargo | Overweight |
| 2023-01-26 | 개시 | Credit Suisse | Outperform |
| 2022-10-18 | 개시 | JMP Securities | Mkt Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-11-03 | 재개 | Jefferies | Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-15 | 개시 | H.C. Wainwright | Buy |
| 2021-05-18 | 재개 | Goldman | Sell |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-03-18 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 개시 | Goldman | Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Underweight |
| 2018-05-11 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-16 | 재확인 | SunTrust | Buy |
| 2017-09-22 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-12 | 재확인 | Needham | Buy |
| 2017-07-14 | 개시 | SunTrust | Buy |
| 2017-03-31 | 개시 | Needham | Buy |
| 2017-03-16 | 개시 | Oppenheimer | Perform |
| 2017-02-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 재확인 | Stifel | Buy |
모두보기
Exelixis Inc 주식(EXEL)의 최신 뉴스
Aug Sectors: Is Exelixis Inc EX9 stock cheap vs fundamentalsEarnings Trend Report & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
Exelixis Announces Key Senior Leadership Hires in Medical Affairs, Sales, & Marketing to Support Commercialization of Cabozan... - ADVFN
See How Rare Bullish Inflows Lift Outliers Like Exelixis - Yahoo Finance
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Trading the Move, Not the Narrative: (EXEL) Edition - Stock Traders Daily
EXELExelixis Announces Second Quarter 2013 Financial Results - ADVFN
Does Exelixis (NASDAQ:EXEL) Deserve A Spot On Your Watchlist? - Yahoo Finance
Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients with Hepatocellular Carcinoma - ADVFN
Exelixis Announces Initiation of Investigator-Sponsored Clinical Trial Combining Cabozantinib & Abiraterone in Men With Castr... - ADVFN
Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafeni... - ADVFN
Exelixis Inc Stock Analysis and ForecastLarge Cap Stability Picks & Double Or Triple Capital - earlytimes.in
Exelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib & Atezolizumab in Metastatic C... - ADVFN
Exelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib in the First-Line Treatment of Metasta... - ADVFN
Exelixis Receives $150 Million Funding Commitment From Deerfield Management - ADVFN
Exelixis Expands the Cabozantinib Development Program Through NCI-CTEP Collaboration - ADVFN
Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refract... - ADVFN
Exelixis Earnings Notes - Trefis
History Review: Is Exelixis Inc stock trading at a premium valuationPortfolio Return Summary & Free Expert Approved Momentum Trade Ideas - moha.gov.vn
Exelixis (MIC:EXEL-RM) EV-to-FCF : 0.00 (As of Dec. 26, 2025) - GuruFocus
Exelixis (HAM:EX9) EV-to-OCF : 13.21 (As of Dec. 22, 2025) - GuruFocus
Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday - MSN
Published on: 2025-12-21 13:28:36 - Улправда
How Exelixis Inc. stock reacts to job market dataMarket Risk Report & Safe Swing Trade Setups - ulpravda.ru
Behavioral Patterns of EXEL and Institutional Flows - news.stocktradersdaily.com
Published on: 2025-12-20 10:46:18 - Улправда
Can Exelixis Inc. stock hit analyst price targetsJuly 2025 Levels & Growth Focused Stock Reports - Улправда
Exelixis and Merck Advance LITESPARK-033: A New Kidney Cancer Combo With High-Stakes Market Potential - TipRanks
Exelixis (FRA:EX9) EV-to-OCF : 12.63 (As of Dec. 19, 2025) - GuruFocus
Will Exelixis Inc. stock benefit from infrastructure spendingJuly 2025 Sector Moves & AI Based Trade Execution Alerts - DonanımHaber
Gap Down: Can Exelixis Inc. (EX9) stock stage a strong rebound this quarterPortfolio Value Report & Short-Term Swing Trade Alerts - DonanımHaber
Is Exelixis Inc. stock a defensive play in 2025July 2025 Levels & Real-Time Market Trend Scan - DonanımHaber
Rally Mode: How analysts revise price targets for Exelixis Inc. (EX9) stock2025 Biggest Moves & Precise Buy Zone Tips - Улправда
Stelios Papadopoulos brings the long view on biotech on The BioCentury Show - biocentury.com
Returns Recap: How Exelixis Inc EX9 stock compares with top peersQuarterly Profit Report & Real-Time Buy Zone Alerts - moha.gov.vn
Why Exelixis Inc. (EX9) stock stays on buy listsWeekly Profit Analysis & Verified Stock Trade Ideas - ulpravda.ru
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
Citizens reiterates Market Outperform rating on Exelixis stock at $50 By Investing.com - Investing.com Canada
Exelixis, Inc.Common Stock (NQ: EXEL - FinancialContent
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: Owlet (OWLT), Exelixis (EXEL) - The Globe and Mail
VP Haley Files To Sell 23,539 Of Exelixis Inc [EXEL] - TradingView — Track All Markets
Exelixis Inc (HAM:EX9)Valuation Measures & Financial Statistics - GuruFocus
Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Exelixis (EXEL) and Natera (NTRA) - theglobeandmail.com
Exelixis Inc (HAM:EX9) Dividend - GuruFocus
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era - The Manila Times
Exelixis (EXEL) Receives a Hold from RBC Capital - theglobeandmail.com
Exelixis stock holds steady as Stifel maintains $43 price target By Investing.com - Investing.com Canada
Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D DaySlideshow (NASDAQ:EXEL) 2025-12-11 - Seeking Alpha
EXEL to Host Research and Development Day in December - GuruFocus
Analyst Upgrade: Can Exelixis Inc EX9 stock stage a strong rebound this quarterSell Signal & Daily Profit Focused Stock Screening - moha.gov.vn
(EXEL) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Exelixis Inc (EXEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):